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Abstract: Many natural and synthetic substances are known to interfere with the 
dynamic assembly of tubulin, preventing the formation of microtubules. In our search 
for potent and selective antitumor agents, a novel series of 1-(3’,4’,5’-
trimethoxybenzoyl)-5-amino-1,2,4-triazoles were synthesized. The compounds had 
different heterocycles, including thiophene, furan or the three isomeric pyridines, and 
they possessed a phenyl ring bearing electron-releasing or electron-withdrawing 
substituents at the 3-position of the 5-amino-1,2,4-triazole system. Most of the twenty-
two tested compounds showed moderate to potent antiproliferative activities against a 
panel of solid tumor and leukemic cell lines, with four (5j, 5k, 5o and 5p) showing 
strong antiproliferative activity (IC50<1 M) against selected cancer cells. Among them, 
several molecules preferentially inhibited the proliferation of leukemic cell lines, showing 
IC50 values 2-100-fold lower for Jurkat and RS4;11 cells than those for the three lines 
derived from solid tumors (HeLa, HT-29 and MCF-7 cells). Compound 5k strongly 
inhibited tubulin assembly, with an IC
50
 value of 0.66 M, half that obtained in 
simultaneous experiments with CA-4 (IC
50
=1.3 M). 
Keywords. Microtubule targeting-agent, structure-activity relationship, tubulin 
polymerization, antiproliferative activity, molecular docking. 
1. Introduction 
The microtubule system of eukaryotic cells, a protein system composed of α-tubulin 
heterodimers in a dynamic equilibrium with microtubules, is a critical element in a variety 
of fundamental cellular processes, including mitosis and cell division, determination and 
maintenance of cell shape, organization of intracellular architecture, secretion, 
intracellular transport and regulation of motility [1-3]. Given their significant role in the 
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cellular functions that are critical to the life cycle of the cell, microtubules are a proven 
molecular target for cancer chemotherapeutic agents and continue to receive substantial 
attention for development of new and improved drugs [4-6].  
Among the distinct classes of tubulin-binding agents that have been identified on the 
basis of their different mechanisms of action and binding sites on tubulin, two groups are 
of particular importance in the clinical treatment of cancer [7, 8]. First are the vinca 
alkaloid microtubule-destabilizers, typified by vinblastine, vincristine, vinorelbine and 
vinflunine. Second are the taxoids, paclitaxel (Taxol), docetaxel (Taxotere) and 
cabazitaxel (Javetana). These compounds act with an opposite effect, interfering with 
microtubule disassembly and stabilizing the microtubule structure. These drugs are used 
to treat a broad range of leukemias and lymphomas as well as many types of solid tumors 
[9-11]. Nevertheless, the clinical success of these two classes of compounds has 
stimulated intensive research aimed at discovering additional microtubule-targeting drugs 
with clinical potential [12].  
A third class of note, due to the discovery of numerous natural products and synthetic 
compounds that target this site, are agents that bind in the colchicine site [13, 14]. Such 
compounds inhibit the polymerization of tubulin into microtubules and display wide 
structural heterogeneity [15, 16]. One of the most notable of these compounds, both for 
its potency and structural simplicity is the naturally occurring cis-stilbene derivative 
combretastatin A-4 (CA-4, 1, Figure 1) [17, 18]. Moreover, several studies have 
documented that compounds targeting the colchicine site also act as powerful vascular 
disrupting agents [19], particularly for the neovasculature of tumors.  
While the vinca alkaloids and the taxoids have well-established roles in the treatment of 
human cancers, no colchicine site inhibitor is currently approved for cancer therapy, 
despite considerable synthetic efforts [20-22], including the preparation of many water-
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soluble prodrugs of CA-4, such as the phosphorylated derivative of combretastatin A-4 
(CA-4P, 2) in phase III clinical trials [23, 24] or the serine amino acid prodrug of 3’-
amino-deoxycombretastatin A-4 (Ombrabulin or AVE8062, 3) [25], which is in phase I 
clinical studies for patients with solid tumors [26].  
These observations emphasize the need to discover novel scaffolds active at the 
colchicine site and amenable to rapid derivatization because such compounds could be 
readily prepared in a cost-effective way by rapid and concise synthetic procedures [27]. 
In addition, several colchicine site binders have been shown to inhibit p53 mutant cell 
lines, and this further emphasizes the importance of novel inhibitors of tubulin assembly 
that have activity against resistant tumors [28]. 
Among the synthetic inhibitors of tubulin polymerization, in a previous article we have 
reported the synthesis and biological evaluation of a series of compounds with general 
structure 4 based on the 1-(3’,4’,5’-trimethoxybenzoyl)-5-amino-1,2,4-triazole 
molecular skeleton, that showed strong antiproliferative activity against a panel of cell 
lines and act as inhibitors of microtubule polymerization by interfering with the 
colchicine site of tubulin [29]. Structure-activity relationships were elucidated with 
various substituents on the phenyl ring of the anilino moiety at the C-3 position of the 
1,2,4-triazole ring, with the p-toluidino derivative 4a exhibiting the best cell growth 
inhibitory activity among the tested compounds, with IC50 values of 0.21-3.2 nM. This 
derivative was also a potent inhibitor of tubulin polymerization, with an IC50 value of 
0.75 M for tubulin assembly.  
A molecular docking study of compound 4a in the colchicine site of tubulin showed that 
the trimethoxyphenyl unit of this derivative is placed in proximity of Cys241, while the 
phenyl ring of the aniline moiety at the 3-position of 1,2,4-triazole ring occupies a 
  
 5 
relatively small hydrophobic region deep in the binding site, establishing a series of non-
polar interactions with amino acids Met259, Thr314 and Lys352 in this subpocket, 
which stabilizes the binding of the molecule in the colchicine site. The same docking 
simulation on compound 4a did not show any hydrogen bond interactions of the amino 
bridge function of the aniline moiety with the amino acid residues located in this small 
pocket of the colchicine site. X-ray crystallographic analysis on compound 4a showed 
the formation of an intramolecular hydrogen bond between the carbonyl oxygen of the 
3’,4’,5’-trimethoxybenzoyl function and the hydrogen of the amino moiety at the 1- and 
5-position, respectively, of the 1,2,4-triazole ring.  
Inspired by these observations and encouraged by the activity obtained with compound 
4a, here we report a new series of 1-(3’,4’,5’-trimethoxybenzoyl)-3-aryl/heteroaryl-5-
amino-1,2,4-triazole analogues with general structure 5, obtained by removing the amino 
function spacer of the anilino group of compounds with general structure 4, connecting 
the aryl/heteroaryl moiety at the 3-position of 1,2,4-triazole ring and keeping constant 
the 3’,4’,5’-trimethoxybenzoyl function and the amino group at the 1- and 5-positions, 
respectively, of the triazole nucleus.  
Thus, once the 1-(3’,4’,5’-trimethoxybenzoyl)-5-amino-1,2,4-triazole motif was 
identified as the minimum structural requirement for activity, modifications were focused 
on varying the substituent at the 3-position of the 1,2,4-triazole ring to develop new 
potent antiproliferative agents and to understand the minimum structural requirements 
for this class of compounds to exhibit potent and selective activity against cancer cell 
lines. The substituents examined included heterocycles such as thien-2-yl (5b), furan-2-yl 
(5c) and the three isomeric pyridines (5d-f) as well as the phenyl ring with various 
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electron-withdrawing (F, Cl, Br, CN and NO2) and electron-releasing (Me, Et, MeO and 
EtO) groups [30]. 
 
Figure 1. Structures of CA-4 (1), CA-4P (2) and Ombrabulin (3). General structure of 1-(3’,4’,5’)-3-
anilino-5-amino-1,2,4-triazole 4. Molecular formulas of synthesized 1-aroyl-3-substituted-5-amino-
1,2,4-triazoles 5a-v. 
While for compounds 5a-t, the 3’,4’,5’-trimethoxyphenyl of the benzoyl moiety at the N-
1 position of the 1,2,4-triazole ring was kept unchanged because this ring is the essential 
structural requirement to maximize potency in a large series of inhibitors of tubulin 
polymerization, such as colchicine, steganacin, CA-4 and podophyllotoxin [31, 32], in an 
effort to further confirm whether the 3,4,5-trimethoxybenzoyl moiety of compound 5k 
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played an essential role for antiproliferative activity, the corresponding 3,4-
dimethoxybenzoyl and 4-methoxybenzoyl derivatives 5u and 5v, respectively, were 
prepared.  
2. Chemistry 
Synthesis of 1-aroyl-3-aryl/heteroaryl-5-amino-1,2,4-triazoles 5a-v was accomplished 
using a three-step procedure described in Scheme 1.  
 
Scheme 1. Reagents. a: aminoguanidine hydrogen carbonate pyridine, 0 °C for 30 min. then 12 h rt; b: 
water, microwave irradiation, 100 W; c: 3',4',5'-(OMe)
3
C
6
H
2
COCl for the preparation of 5a-t, 4',5'-
(OMe)
2
C
6
H
3
COCl or 4'-OMe-C
6
H
4
COCl for the synthesis of 5u and 5v, respectively, pyridine, 0 °C. 
The required 3-aryl/heteroaryl-5-amino-1,2,4-triazoles 8a-t were synthesized by reaction 
of aroyl/heteroaroyl chloride 6a-t with aminoguanidine hydrogen carbonate using 
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pyridine as solvent to furnish the corresponding aroyl/heteroaryl amidoguanidines 7a-t, 
followed by subsequent ring closure of the intermediate in water under microwave 
irradiation. Treatment of 8a-t with an equimolar quantity of 3’,4’,5’-trimethoxybenzoyl 
chloride resulted in the formation of compounds 5a-t. Using the same synthetic 
methodology, compounds 5u and 5v were prepared by the reaction of 3-(p-tolyl)-5-
amino-1,2,4-triazole 8k with 4’,5’-dimethoxybenzoyl chloride and 4’-methoxybenzoyl 
chloride, respectively. 
3. Biological Results and Discussion 
3.1. In vitro antiproliferative activities.  
The synthesized compounds 5a-v were tested for their antiproliferative activity against a 
panel of five human cancer cell lines, T-leukemia (Jurkat), acute lymphoblastic leukemia 
(RS4;11), cervix carcinoma (HeLa), colon adenocarcinoma (HT29) and breast 
adenocarcinoma (MCF-7), by the MTT assay for 48 h. The results are summarized in 
Table 1, using CA-4 (1) and 4a as positive controls. In general, the antiproliferative 
activities of compounds 5a, 5h, 5k-r and 5u were greater against the leukemia cells as 
compared with the solid tumor cells.  
The unsubstituted phenyl derivative 5a showed modest antiproliferative activity (IC50>10 
M) against HT29 and MCF-7 cells, while it was more active, with IC50 values of 1.4, 
1.7 and 6.6 M, against Jurkat, RS4;11 and HeLa cells, respectively.  
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Table 1. In vitro inhibitory effects of compounds 4a, 5a-v and CA-4 
 
Compd  
IC50 
a
(M)  
Jurkat RS4;11 HeLa HT29 MCF-7 Average 
5a 1.4±0.3 1.7±0.1 6.6±1.3 27.3±9.
6 
19.1±2.
0 
11.2 
5b 43.3±7.3 17.7±7.7 10.5±2.
1 
15.9±1.
3 
19.9±3.
1 
21.5 
5c >100 44.3±16.
8 
21.3±1.
6 
18.5±2.
2 
19.1±1.
1 
nc 
5d >100 10.8±3.2 17.7±1.
3 
23.9±2.
6 
21.9±3.
1 
nc 
5e >100 68.3±10.
9 
>100 >100 >100 nc 
5f >100 49.0±4.6 >100 >100 >100 nc 
5g 8.1±1.3 4.0±0.5 5.4±1.6 4.7±1.5 7.2±3.2 5.9 
5h 1.4±0.8 1.3±0.5 4.0±0.5 3.8±1.4 2.7±0.7 2.6 
5i >100 >100 >100 >100 >100 >100 
5j 2.6±0.6 0.8±0.2 2.8±0.9 0.5±0.1 5.6±1.6 2.5 
5k 0.5±0.2 1.8±0.06 5.5±1.2 4.9±0.8 3.6±1.0 3.3 
5l 3.9±0.1 4.2±0.9 10.1±2.6 13.2±1.8 11.5±1.4 8.6 
5m 34.0±0.6 19.3±0.9 19.8±3.1 25.2±2.5 23.6±3.6 24.4 
5n 2.6±0.09 2.2±0.1 15.6±1.9 21.1±2.9 18.6±2.1 12.0 
5o 1.2±0.5 0.3±0.1 6.6±1.3 23.4±2.1 9.6±1.5 8.2 
5p 4.0±1.3 0.9±0.02 9.8±1.2 11.2±1.1 10.3±2.0 7.2 
5q 4.3±0.8 8.5±1.5 11.2±2.3 19.9±1.6 18.8±2.6 12.5 
5r 4.0±0.1 3.6±1.1 9.8±1.1 12.1±1.5 10.2±0.9 7.9 
5s >100 99.3±22.8 >100 >100 >100 nc 
5t 59.3±17.6 47.7±9.3 75.6±3.5 88.9±5.2 82.3±3.9 70.8 
5u 9.3±1.1 1.8±0.6 15.1±1.
9 
17.2±2.
5 
13.2±1.
6 
11.3 
5v >100 38.9±7.2 45.5±3.
6 
65.3±4.
2 
39.3±4.
1 
nc 
4a (nM) 0.8±0.3 nd 3.2±1.3 0.8±0.1 1±0.6 nc 
CA-4 (nM) 0.8±0.2 370±100 4±1 180±30 5±0.6 112 
a
IC
50
= compound concentration required to inhibit tumor cell proliferation by 50%. 
nc= not calculated 
nd=not determined 
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In contrast, if the phenyl at position 3 was replaced by the biososteric 2’-thienyl (5b), 2’-
furanyl (5c) or the three isomeric pyridines (compounds 5d-f), significantly reduced 
activity was observed against the leukemia cell lines, while derivatives 5b-d, but not 5e-f, 
were comparable to 5a against the solid tumor cells. Comparing the activities of p-tolyl 
and p-toluidino derivatives 5k and 4a, respectively, the presence of the amino (NH) 
spacer between the p-tolyl group and the 3-position of 1,2,4-triazole ring played a 
crucial role in affecting antiproliferative activity, with the p-tolyl derivative 5k almost 
three orders of magnitude less potent than the p-toluidino derivative 4a.   
The data presented in Table 1 for compounds 5g-t examine the effects of different 
substituents on the phenyl ring on antiproliferative activity. Considering the average IC50 
against the five cell lines, compounds 5h, 5j and 5k were the most active in the series, 
with mean IC50’s, respectively, of 2.6, 2.5 and 3.3 µM. In addition, these data showed 
that the nature and the location of the substituent on the phenyl at the 3-position of the 
1,2,4-triazole core played a critical role in antiproliferative activities, and only a few 
compounds showed any IC50 values lower than 1 M against any of the cancer cell lines. 
RS4;11 and HT29 cells were the most sensitive to the p-bromophenyl derivative 5j, with 
IC50 values of 0.8 and 0.5 M, respectively. The p-tolyl compound 5k showed an IC50 of 
0.5 M against the Jurkat cells, and the p-methoxyphenyl derivative 5o and its isomeric 
m-methoxy analogue 5p had IC50 values of 0.3 and 0.9 M, respectively, against RS4;11 
cells.  
Substituents clearly had effects on antiproliferative activity. For example, 
antiproliferative activity was almost eliminated with a m-Cl (5i) or a m-CN (5s). 
Compounds with other meta-substituents, such as methyl (5l) or methoxy (5p), had 
reasonable activity relative to 5a (in terms of mean IC50, 8.6, 7.2 and 11.2 µM, 
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respectively). With para-substituents, the best activities, in terms of mean IC50 values 
(2.5-3.3 µM) occurred with a p-Cl (5h), a p-Br (5j) and a p-CH3 (5k). A second group 
of para-substituents had mean IC50 values in the 5.9-12.5 µM range (p-F, 5g; p-ethyl, 
5n; p-methoxy, 5o; p-ethoxy, 5q; p-CN, 5r). Compound 5t, p-NO2, was an outlier with 
a mean IC50 of 70.8 µM. With this large group of para-substituents, there was no clear 
pattern in terms of electron-withdrawing or electron-donating properties. The only 
compound with an ortho-substituent (5m, o-CH3) was relatively inactive with a mean 
IC50 of 24 µM, as compared with 3.3 and 8.6 µM for its para and meta analogs 5k and 
5l, respectively. In terms of position, para seems best, ortho worst, based on the methyl 
series 5k-m. The superiority of the para-substituent over the meta held in every case 
except for the methoxy pair, where the mean IC50 for 5p (meta) was 7.2 while that for 
5o (para) was 8.2. 
Turning to individual cell lines, comparing the antiproliferative activities of compounds 
5g (p-F), 5h (p-Cl) and 5j (p-Br), revealed that on RS4;11, HeLa and HT-29 cells, the 
antiproliferative activity increased with increasing size of the halogen atom at the para-
position of the phenyl ring. In contrast, for Jurkat and MCF7 cells, the effect of the 
halogen atom on activity was chlorine>bromine>fluorine. Thus, replacement of the 
fluorine at the para-position of the phenyl ring with a chlorine (compounds 5g and 5h, 
respectively) led to 6-, 3- and 2.5-fold increase of potency against Jurkat, RS4;11 and 
MCF-7 cells, while the activity was unchanged against HeLa and HT29 cells. Moving the 
chlorine from the para- to the meta-position on the phenyl ring (compounds 5h and 5i, 
respectively) eliminated antiproliferative activity. A similar loss of potency was observed 
for the para-cyano derivative 5r versus the isomeric meta-cyano analogue 5s. Replacing 
para-chlorine with bromine (compounds 5h and 5j, respectively) had a contrasting 
  
 12 
effect. Derivative 5j was 2-fold less potent than chlorine agent 5h against Jurkat and 
MCF-7 cells, while it retained activity against HeLa cells. Nevertheless, the p-
bromophenyl derivative 5j showed strong antiproliferative activities in the 
submicromolar range against RS4;11 and HT29 cells, with IC50 values of 0.8 and 0.5 
M, respectively, and was thus 2- and 7-fold more potent than its chlorine counterpart 
5h.  
It should be noted that replacement of the weak electron-withdrawing fluorine with the 
weak electron-releasing methyl group, to furnish derivative 5k, significantly improved 
potency from 2- to 16- fold against Jurkat, RS4;11 and MCF-7 cells, while the two 
derivatives showed similar activity toward HeLa and HT29 cells. However, the 
introduction of the methyl at the para-position of the phenyl ring (compound 5k) 
enhanced activity from 3- to 5-fold against Jurkat, HT-29 and MCF-7 cells in 
comparison with the unsubstituted phenyl analogue 5a, while the two compounds are 
equipotent against RS4;11 and HeLa cells. 
To compare the effects of ortho-, meta- and para-methyl substitution on the phenyl ring, 
the m-tolyl and o-tolyl derivatives 5l and 5m, respectively, were also synthesized and 
showed different activities, indicating that the position of the methyl group is crucial for 
antiproliferative activity. The o-tolyl derivative 5m was 3-70-fold less potent the p-tolyl 
analogue 5k, whereas the m-tolyl derivative 5l had intermediate activity, being 2-7-fold 
less active than the p-tolyl isomer 5k against all cancer cell lines.  
As noted above, our findings indicate that a methoxy group located at the para-position 
of the phenyl ring (compound 5o) resulted in strong antiproliferative activity against 
RS4;11 cells (IC50=0.3 M), while shifting it to the meta-position, to furnish derivative 
5p, decreased activity 3-fold. A similar effect was observed against Jurkat and HeLa 
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cells. Additionally, our findings indicate that moving substituents from the para- to the 
meta- or ortho-position on the phenyl ring was generally not favorable for maintaining 
antiproliferative activity within the series of analogues reported here (5h vs. 5i, 5k vs. 5l 
and 5m, 5o vs. 5p and 5r vs. 5s).  
Replacement of p-methoxy with p-ethoxy (compounds 5o and 5q, respectively) reduced 
activity from 2- to 28-fold against Jurkat, RS4;11, Hela and MCF-7 cells, although 
activity was retained against HT29 cells.  
Compound 5u, with a 3’,4’-dimethoxybenzoyl group at the N1-position of the 3-(p-toly)-
5-amino-1,2,4-triazole system, had 3-18-fold reduced cell growth inhibitory activity as 
compared with the 3’,4’,5’-trimethoxybenzoyl derivative 5k against four of the five cell 
lines, but the two derivatives were equipotent against RS4;11 cells. The 4’-
methoxybenzoyl analogue 5v showed substantially reduced activity (IC50>30 M) 
compared to 5k in all cell lines. 
Among the electron-withdrawing groups, introduction of the nitro substituent, resulted 
in compound (5t) with reduced antiproliferative activity compared with those bearing 
halogen or cyano substituents.  
In summary, small structural modifications are responsible for great variations of the IC50 
values obtained against the cancer cell lines studied, with the methyl and methoxy 
moieties (compounds 5k and 5o, respectively) being optimal at the para-position of the 
phenyl at the 3-position of the 1,2,4-triazole ring.  
3.2. In vitro inhibition of tubulin polymerization and colchicine binding. 
To investigate whether the antiproliferative activities of selected substituted phenyl 
derivatives 5j (p-Br), 5k (p-Me), 5o (p-OMe) and 5p (m-OMe) derived from an 
interaction with tubulin, these agents were evaluated for their ability to inhibit tubulin 
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polymerization and for effects on the binding of [
3
H]colchicine to tubulin (Table 2). For 
comparison, CA-4 (1) and 4a were examined in contemporaneous experiments as 
reference compounds. 
Table 2. Inhibition of tubulin polymerization and colchicine binding by compounds 
CA-4, 4a, 5j-k and 5o-p. 
 
Compound 
Tubulin assembly
a 
IC50±SD (M) 
Colchicine binding 
b 
% ±SD 
5j >20 17±6 
5k 0.66±0.09 61±4 
5o 0.97±0.1 51±3 
5p >20 3.8±0.2 
4a 0.75±0.1 92±2 
CA-4 1.2±0.1 98±0.5 
a
 Inhibition of tubulin polymerization. Tubulin was at 10 M. 
b
 Inhibition of [
3
H]colchicine binding. Tubulin, colchicine and tested compound were at 1, 5 and 5 M, 
respectively. 
The p-tolyl derivative 5k, the most potent compound of the series against Jurkat (T-
leukemia) cells, was found to be also a strong inhibitor of tubulin polymerization, with an 
IC50 value of 0.66 M, nearly twice as potent as CA-4 (IC50:1.2 M). Note that 4a had 
much greater antiproliferative activity than 5k, despite the similar effects on tubulin 
assembly. Such discrepancies in antitubulin versus antiproliferative activity are not 
infrequently observed, but the reasons are usually uncertain, as is the case here. Among 
possible explanations is that we are using bovine brain tubulin in the former studies, and 
its composition in terms of tubulin isotypes differs significantly from that of different 
human cancer cell lines [33]. 
Compound 5o, as the most potent derivative of the series against RS4;11 (acute 
lymphoblastic leukemia) cells, strongly inhibited tubulin polymerization (IC50:0.97 M) 
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with activity comparable to that of CA-4. The results obtained demonstrate that the 
antiproliferative activities of compounds 5k and 5o are related to inhibition of tubulin 
polymerization. It is intriguing to note that compounds 5j and 5p were inactive as 
inhibitors of tubulin polymerization, with minimal activity (IC50>20 M), although these 
derivatives demonstrated significant antiproliferative activity against RS4;11 cells, with 
IC50 values of 0.8 and 0.9 M, respectively, only 3-fold less potent as antiproliferative 
agents relative to 5o against this cancer cell line. The weak activity against tubulin 
suggests the possibility that compounds 5j and 5p may possess an additional mechanism 
of inhibition of cancer cell growth beyond that attributable to the tubulin-based 
mechanism.  
Comparing the IC50 values of the inhibition of tubulin assembly for compounds 5o and 
5p, corresponding to 0.97 and >20 M, respectively, it appears that a small structural 
modification, such as moving the methoxy group from the para- to the meta-position of 
the phenyl ring, is responsible for great variation in antitubulin activity, suggesting that 
there is a space-limited pocket surrounding the phenyl at the 3-position of 1,2,4-triazole 
ring.  
In the colchicine binding studies, compounds 5k and 5o displayed 61% and 51%, 
respectively, inhibition of [
3
H]colchicine binding at 5 M, with 1 µM tubulin. Both 
compounds were significantly less potent than CA-4 in this assay, despite their greater 
potency as inhibitors of tubulin assembly. Such differences are commonly observed, and 
CA-4 is a particularly potent inhibitor of [
3
H]colchicine binding [17, 18]. The data 
suggested that compounds 5k and 5o bind to the colchicine site and inhibit the 
polymerization of tubulin. In this assay, derivative 4a potently inhibited the binding of 
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[
3
H]colchicine to tubulin, and with 92% inhibition was 1.5-fold more active than 5k, 
which in this experiment inhibited colchicine binding by 61%. 
In general, in these experiments, inhibition of [
3
H]colchicine binding correlated more 
closely with inhibition of tubulin assembly than with antiproliferative activity. Thus, 
compound 5o was as active as CA-4 as an inhibitor of tubulin polymerization, although 
this derivative was less active in its effects on cell growth against the whole panel of 
cancer cell lines. 
3.3. Molecular modeling studies. 
In order to further understand the different activity profiles of the tested compounds, 
several molecular modeling studies were performed. According to a recent publication, 
the tubulin colchicine domain is formed by a main site, where colchicine binds (zone 1), 
and two additional neighboring pockets (zones 2 and 3) [34]. After studying the tubulin 
crystal structures in complex with different ligands, these authors concluded that 
globular or butterfly like shaped molecules bind to zones 1 and 2, mimicking colchicine 
binding, whereas planar compounds tend to bind in zones 2 and 3 [34]. In order to 
identify the most likely binding area of the new derivatives, a series of docking studies 
were performed with compounds 5j, 5k, 5o and 5p. Two different tubulin crystal 
structures were used: one co-crystallized with colchicine (PDB ID: 4O2B), representing 
the colchicine-like binding site area (zones 1 and 2), and one co-crystallized with the 
inhibitor G2N (PDB ID: 3N2G), representing the planar compounds binding in zones 2 
and 3 [35, 36]. The 3N2G crystal structure was chosen because the ligand included a 
free amino group in the central portion of G2N, which is a feature also present in the 
compounds we examined. Docking studies were performed using the Glide SP method, 
and the results were then refined using Glide XP scoring [37]. The proposed binding 
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modes of the two active derivatives 5k and 5o in the colchicine binding site are 
consistent with that previously reported for similar derivatives, and these binding modes 
are very similar to that found for the co-crystallized colchicine. In these models, the 
trimethoxyphenyl ring is in proximity of βCys241, with the 4’-methylphenyl or the 4’-
methoxyphenyl ring occupying the area close to βMet259 [29] (Figure 2A).  
 
Figure 2. Proposed binding for compound 5k (A, carbon atoms in purple) and 5p (B, carbon atoms in 
orange) in the colchicine binding site (4O2B). Co-crystallized colchicine is shown in green. The 
hydrophobic subpocket nearby, including Met259, is highlighted with a red surface. Note how the 3’-
methoxyphenyl ring of 5p is pointing in the opposite direction of the co-crystallised colchicine, as 
compared with the analogous structural feature of 5k as shown in Panel A. 
We found no plausible binding poses for the two inactive compounds, 5p and 5j, by the 
docking program, but there was a binding pose for 5p (shown in Figure 2B), where the 
3-methoxyphenyl ring pointed in the opposite direction relative to the co-crystallized 
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colchicine. We then examined the potential binding mode of the new compounds into the 
G2N site. Even though the compounds occupy the binding site in a very similar manner 
to the co-crystallized inhibitor, it was not possible to rationalize the differences seen in 
the tubulin polymerization inhibition assay, which appeared to be linked to the 
substituent on the phenyl ring (Figure 3A and 3B). 
 
 
 
 
 
 
 
 
 
Figure 3. Proposed binding for compound 5k (A, carbon atoms in purple) and 5p (B, carbon atoms in 
orange) in the G2N binding site (3N2G). Co-crystallized G2N is shown in yellow. The different 
location of this binding site in comparison with the colchicine binding site, can be easily seen by noting 
the spatial orientation of Cys241. No substantial differences in the binding modes were found between 
the active (5k) and inactive (5p) derivatives. 
Based on the docking results, a binding mode similar to that of colchicine might be more 
relevant for these compounds (zone 1). However, the planar conformation of the 
molecules and the relatively low colchicine binding competition values found in the 
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biological assay, would suggest that the binding site for these new compounds only 
partially overlaps the one for colchicine and could involve only zones 2 and 3 (3N2G). 
Therefore, in order to help select the potential binding site from the two choices 
presented in Figures 2 and 3, a series of short 20 ns molecular dynamic (MD) simulations 
on selected compounds (5k, 5o, 5p) were performed using the Desmond software 
package [38]. The relative binding free energies (∆Gbinding) of the compounds were then 
calculated using the Prime/MM-GBSA based calculation method [39]. All the protein-
ligand systems reached stability after an initial 6 ns of equilibration, as shown by the C-
alpha RMSD variation (see Figure S1 in the Supporting Information data), so therefore 
only the remaining 14 ns of the simulation were considered in our analysis.  
 
Figure 4. Ligand-protein interaction diagram for compound 5k in the two different binding sites, 4O2B 
(a) and 3N2G (b). The most persistent interactions formed during the MD simulation are reported 
together with the interaction strengths. The interaction between the methoxy groups and Cys241, 
mediated by a water bridge, is only present in the colchicine binding site simulation. The first 6 ns of 
MD, in which the protein-ligand system reached stability, were excluded from the diagram. 
The position of the trimethoxyphenyl ring and the disposition of the substituted phenyl 
ring near the area of βMet259 were maintained during the entire simulation of 5k and 5o, 
confirming the reliability of the docking in predicting the binding mode in the colchicine 
binding site (4O2B). In particular, water bridge formation between the methoxy groups 
and βCys241 and the interaction between βLys352 and the central triazole ring were 
seen for both derivatives during the entire MD, potentially contributing to protein-ligand 
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stability (Figure 4A). Instead, the proposed binding for 5p was very variable, with the 
compound not able to occupy in a stable manner the binding area during the whole 
simulation. In the case of the G2N binding site, for all the derivatives studied, the 
trimethoxyphenyl ring was no longer able to interact with Cys241, moving away from 
this residue and potentially losing a fundamental interaction point for the tubulin 
inhibition function (Figure 4B). Table 3 reports the calculated ligand-interaction energies 
with the two different binding sites for the compounds analysed by MD. Overall, the 
∆Gbinding calculated for 5k and 5o in the colchicine binding site (4O2B) is lower than the 
one estimated for each corresponding compound in the G2N binding area, potentially 
meaning that the colchicine binding site ligands system is more stable in comparison with 
the G2N-binding site ligands system, and therefore the former is the more likely binding 
area for the these new derivatives.  
Table 3. Calculated ligand-interaction energies for the compounds analyzed by MD 
simulation. 
Compound ∆Gbinding (kJ/mol)
a
±SD 
4O2B 
∆Gbinding (kJ/mol)
a
±SD 
3N2G 
5k -69.512 ± 1.769 -58.685 ± 3.338 
5o -74.471 ± 0.400 -69.161 ± 3.379 
5p -59.613 ± 1.964 -65.809 ± 2.318 
a Average values calculated as mean of three ΔGbinding obtained from three independent MD simulations 
(triplicate) for each compound. For each replicate, the average ΔGbinding value was calculated excluding 
the first 6 ns of MD in which the protein-ligand system reached stability. Standard deviation (SD) is 
reported. 
Water bridge formation between the methoxy groups and βCys241, the interaction 
between βLys352 and the central 1,2,4-triazole ring and the accommodation of the 
substituted phenyl ring in the hydrophobic sub-pocket near βMet259 could confer 
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stability on the protein-ligand system leading to lower energy values, reflecting binding 
of the ligand resulting in inhibition of tubulin polymerization. The insertion of the 
methoxy group in position 3’, as in compound 5p, abolishes inhibition of tubulin 
polymerization, and a completely different binding pose with a higher calculated ∆Gbinding 
value was found. The higher ∆Gbinding values obtained for the G2N-binding site is an 
indication that the protein-ligand system could be less stable if the compounds bind to 
this site. Moreover, the higher standard deviation calculated for the three average 
∆Gbinding values may indicate that the ligand binding in this area was very variable in all 
the performed simulations, giving a further indication that it is very unlikely that the 
G2N-binding site is the potential binding site for these new derivatives. 
3.4 Analysis of cell cycle effects.  
The effects of 24 h treatments with different concentrations of 5k and 5p on cell cycle 
progression in HeLa cells were determined by flow cytometry (Figure 5). Compound 5k 
caused a significant G2/M arrest in a concentration-dependent manner in HeLa cells, 
with an increase in G2/M cells occurring at 5 µM. The cell cycle arrest in G2/M phase 
was accompanied by a slight reduction of both G1 and S phase cells. In contrast, 
treatment with compound 5p even at high concentrations (20 µM) had no effect on cell 
cycle distribution, and, in particular, it did not cause the increase in G2-M cells always 
observed with antitubulin agents, in good agreement with the negative result observed in 
the tubulin polymerization assay. It is worthwhile noting that similar results wereb also 
obtained after 48 h treatments (data not shown). 
  
 22 
 
Figure 5. Percentage of cells in each phase of the cell cycle in HeLa cells treated with compounds 5k 
and 5p at the indicated concentrations for 24 h. Cells were fixed and labeled with PI and analyzed by 
flow cytometry as described in the Experimental Section. Data are expressed as mean ± SEM. 
3.5 Compounds 5k and 5p both induce apoptosis.  
To evaluate the mode of cell death induced by 5k and 5p, a biparametric cytofluorimetric 
analysis was performed using propidium iodide (PI), which stains DNA and enters only 
dead cells, and fluorescent immunolabeling of the protein annexin-V, which binds to 
phosphatidyl serine in a highly selective manner.
 
Dual staining for annexin-V and with PI 
permits discrimination between live cells (annexin-V
-
/PI
-
), early apoptotic cells (annexin-
V
+
/PI
-
), late apoptotic cells (annexin-V
+
/PI
+
) and necrotic cells (annexin-V
-
/PI
+
). As 
shown in Figure 6, HeLa cells treated with 5k or 5p showed an accumulation of annexin-
V positive cells in comparison with the control, in a concentration- and time-dependent 
manner.  
 
 
  
 23 
C
tr
5
 
M
1
0
 
M
2
0
 
M
0
2 0
4 0
6 0
8 0
1 0 0
2 4  h
5 k
C
e
ll
s
 (
%
)
A - /P I-
A + /P I-
A + /P I+
A - /P I+
C
tr
5
 
M
1
0
 
M
2
0
 
M
0
2 0
4 0
6 0
8 0
1 0 0
 4 8  h
5 k
C
e
ll
s
 (
%
)
A - /P I-
A + /P I-
A + /P I+
A - /P I+
 
C
tr
5
 
M
1
0
 
M
2
0
 
M
0
2 0
4 0
6 0
8 0
1 0 0
2 4  h
5 p
C
e
ll
s
 (
%
)
A - /P I-
A + /P I-
A + /P I+
A - /P I+
C
tr
5
 
M
1
0
 
M
2
0
 
M
0
2 0
4 0
6 0
8 0
1 0 0
 4 8  h
5 p
C
e
ll
s
 (
%
)
A - /P I-
A + /P I-
A + /P I+
A - /P I+
 
Figure 6. Flow cytometric analysis of apoptotic cells after treatment of HeLa cells with compounds 5k 
or 5p at the indicated concentrations after incubation for 24 or 48 h. The cells were harvested and 
labeled with annexin-V-FITC and PI and analyzed by flow cytometry. Data are represented as 
mean±SEM of three independent experiments. 
4. Conclusions 
We have discovered a new class of simple synthetic inhibitors of tubulin polymerization 
based on the 1-(3’,4’,5’-trimethoxybenzoyl)-3-aryl/heteroaryl-5-amino-1,2,4-triazole 
molecular skeleton. The introduction of different electron-withdrawing (F, Cl and Br) 
and electron-releasing (Me and OMe) groups at the para-position of the phenyl ring had 
variable effects on cell growth inhibitory activity against different cancer cell lines, 
revealing an avenue for future optimization. An enhancement of antiproliferative activity 
was observed against leukemic RS4;11 cells by the introduction of a bromine or a 
methoxy group at the para-position of the phenyl ring or moving the methoxy group 
from the para- to the meta-position (compounds 5j, 5o and 5p, respectively).  
  
 24 
Only compounds 5j (p-Br), 5k (p-Me), 5o (p-OMe) and 5p (m-OMe) showed cell 
growth inhibitory activities in the submicromolar range (IC50<1 M) against selected 
cancer cell lines, with 5j, 5k and 5o as the most potent antiproliferative agents against 
HT29, Jurkat and RS4;11 cells, with IC50 values of 0.5, 0.5 and 0.3 M.  
Compounds 5k and 5o, the most potent antiproliferative agents against Jurkat and 
RS4;11 leukemic cells, respectively, proved to be strong inhibitors of tubulin 
polymerization (IC50:0.66 M for 5k, IC50:0.97 M for 5o). These findings indicate that 
the p-tolyl as well as the p-methoxyphenyl at the 3-position of 5-amino-1,2,4-triazole 
core are crucial moieties for inhibition of tubulin polymerization. Analogues 5j (p-Br) 
and 5p (m-OMe), with antiproliferative activity at submicromolar concentrations against 
RS4;11 cells, showed IC50>20 M in the tubulin polymerization assay. This, together 
with the minimal cell cycle effect of 5p, implies that these derivatives act against another 
target. The complete loss of antitubulin activity of the m-OMe analogue 5p as compared 
with the p-OMe counterpart 5o was presumably due primarily to steric limitations 
around the phenyl ring at the C-3 position of the 1,2,4-triazole core. Although 
derivatives 5j and 5p were 3-fold less active as antiproliferative agents as compared with 
compound 5o against RS4;11 cells, the weak tubulin polymerization inhibition of 5j and 
5p suggested that the mechanism of antiproliferative activity of these two molecules was 
different from inhibition of tubulin polymerization. These results were also confirmed by 
analysis of cell cycle data in which only compound 5k arrested cells in the G2/M phase, 
in good agreement with the tubulin polymerization data. Removing the amino spacer 
between the p-tolyl moiety and the 1,2,4-triazole ring of 4a, to furnish derivative 5k, 
resulted in a substantial reduction in antiproliferative activity, while the two compounds 
were equipotent as inhibitors of tubulin polymerization. Assuming similar tubulin 
  
 25 
content in the different cell lines, the most reasonable explanation for these differences 
is that the tubulin assay is not a good predictor of antiproliferative activity in cells. 
Finally, several compounds, such as 5j, 5k, 5o and 5p, retain antiproliferative activity at 
submicromolar levels toward leukemic cells, and this should permit the future design of 
compounds specifically directed against leukemia.  
5. Experimental Protocols. 
5.1. Chemistry.  
5.1.1. Materials and Methods.  
1
H NMR spectra were recorded on either a Bruker AC 200 or a Varian 400 Mercury 
Plus spectrometer, while 
13
C NMR spectra were recorded on Varian 400 Mercury Plus 
spectrometer. Chemical shifts () are given in ppm upfield from tetramethylsilane as 
internal standard, and the spectra were recorded in appropriate deuterated solvents, as 
indicated. Positive-ion electrospray ionization (ESI) mass spectra were recorded on a 
double-focusing Finnigan MAT 95 instrument with BE geometry. Melting points (mp) 
were determined on a Buchi-Tottoli apparatus and are uncorrected. Microwave-assisted 
reactions were performed on a CEM Discover SP single-mode reactor (2450 MHz). 
Closed vessel experiments were carried out in capped microwave-dedicated vials (10 
mL). The temperature of the reaction was monitored by an external fiber optic 
temperature sensor. After completion of the reaction, the mixture was cooled to 25 °C 
via air-jet cooling. All products reported showed 
1
H and 
13
C NMR spectra in agreement 
with the assigned structures. The purity of tested compounds was determined by 
combustion elemental analyses conducted by the Microanalytical Laboratory of the 
Chemistry Department of the University of Ferrara with a Yanagimoto MT-5 CHN 
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recorder elemental analyzer. All tested compounds yielded data consistent with a purity 
of at least 95% as compared with the theoretical values. All reactions were carried out 
under an inert atmosphere of dry nitrogen. Standard syringe techniques were used for 
transferring dry solvents. Reaction courses and product mixtures were routinely 
monitored by TLC on silica gel (precoated F254 Merck plates), and compounds were 
visualized with aqueous KMnO4. Flash chromatography was performed using 230-400 
mesh silica gel and the indicated solvent system. Organic solutions were dried over 
anhydrous Na2SO4. 
5.1.2. General method A for the synthesis of compounds 7a-t.   
To a stirred solution of aminoguanidine hydrogen carbonate (2.8 g, 20 mmol) in dry 
pyridine (30 mL) cooled at 0 °C was added the appropriate hetero/aroyl chloride 6a-t 
(20 mol, 1 equiv.) in small portions. The reaction mixture was stirred for 30 min at 0 °C 
and then overnight at room temperature. Pyridine was removed by evaporation under 
reduced pressure, and the residue was dissolved with water (20 mL). The stirred solution 
was cooled with an ice bath, and an aqueous solution of NaOH (2 N) was slowly added 
(pH=10-11). The resultant solid was collected by filtration, washed with ethyl ether (15 
mL) and dried overnight under vacuum on P2O5 to afford compounds 7a-t. Compounds 
7a and 7f showed spectroscopic and analytical data in agreement with those previously 
published [40]. Compounds 7e, 7f, 7h, 7i and 7o were previously published, although 
neither their spectroscopic and analytical data were reported [30]. 
5.1.2.1. 2-Benzoylhydrazinecarboximidamide (7a). Synthesized according to method A, 
compound 7a was obtained as a white solid (yield 61%); mp 184-185 °C. 
1
H-NMR (d6-
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DMSO) : 6.84 (bs, 2H), 6.98 (bs, 2H), 7.28 (m, 3H), 7.86 (m, 2H), 10.5 (bs, 1H). MS 
(ESI): [M+1]
+
=179.25.  
5.1.2.2. 2-(Thiophene-2-carbonyl)hydrazinecarboximidamide (7b). Synthesized 
according to method A, derivative 7b was obtained as a yellow solid (yield 53%); mp 
210-212 °C. 
1
H-NMR (d6-DMSO) : 6.77 (bs, 4H), 6.94 (dd, J=4.8 and 3.6 Hz, 1H), 
7.33 (m, 2H), 10.4 (bs, 1H). MS (ESI): [M+1]
+
=185.07.  
5.1.2.3. 2-(Furan-2-carbonyl)hydrazinecarboximidamide (7c). Synthesized according to 
method A, derivative 7c was obtained as a white solid (yield 44%); mp 214-215 °C. 
1
H-
NMR (d6-DMSO) : 6.39 (dd, J=3.2 and 1.6 Hz, 1H), 6.57 (d, J=3.2 Hz, 1H), 6.67 (bs, 
4H), 7.51 (d, J=1,6 Hz, 1H), 10.4 (bs, 1H). MS (ESI): [M+1]
+
=169.22.  
5.1.2.4. 2-Picolinoylhydrazinecarboximidamide (7d). Synthesized according to method 
A, derivative 7d was obtained as a yellow solid (yield 54%); mp 210-211 °C. 
1
H-NMR 
(d6-DMSO) : 6.78 (bs, 4H), 7.62 (dd, J=6.8 and 7.0 Hz, 1H), 8.06 (m, 1H), 8.72 (d, 
J=6.8 Hz, 1H), 9.10 (d, J=2.0 Hz, 1H), 10.3 (bs, 1H). MS (ESI): [M+1]
+
=180.56.  
5.1.2.5. 2-Nicotinoylhydrazinecarboximidamide (7e). Synthesized according to method 
A, derivative 7e was obtained as a yellow solid (yield 62%); mp 203-205 °C. 
1
H-NMR 
(d6-DMSO) : 6.86 (bs, 4H), 7.26 (m, 1H), 8.19 (dd, J=5.8 and 2.0 Hz, 1H), 8.43 (dd, 
J=4.8 and 1.6 Hz Hz, 1H), 9.10 (d, J=2.0 Hz, 1H), 10.2 (bs, 1H). MS (ESI): 
[M+1]
+
=180.24.  
5.1.2.6. 2-Isonicotinoylhydrazinecarboximidamide (7f). Synthesized according to 
method A, derivative 7f was obtained as a yellow solid (yield 56%); mp 187-189 °C. 
1
H-
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NMR (d6-DMSO) : 6.94 (bs, 4H), 7.82 (dd, J=4.4 and 1.2 Hz, 2H), 8.47 (dd, J=4.4 
and 1.2 Hz, 2H), 10.2 (bs, 1H). MS (ESI): [M+1]
+
=180.36.  
5.1.2.7. 2-(4-Fluorobenzoyl)hydrazinecarboximidamide (7g). Synthesized according to 
method A, compound 7g was obtained as a white solid (yield 50%); mp 187-188 °C. 
1
H-
NMR (d6-DMSO) : 6.74 (bs, 2H), 6.86 (bs, 2H), 7.02 (t, J=9.0 Hz, 2H), 7.93 (dd, 
J=9.0 and 6.2 Hz, 2H), 10.4 (bs, 1H). MS (ESI): [M+1]
+
=197.21.  
5.1.2.8. 2-(4-Chlorobenzoyl)hydrazinecarboximidamide (7h). Synthesized according to 
method A, compound 7h was obtained as a yellow solid (yield 43%); mp 188-189 °C. 
1
H-NMR (d6-DMSO) : 6.80 (bs, 2H), 6.95 (bs, 2H), 7.30 (d, J=8.6 Hz, 2H), 7.92 (d, 
J=8.6 Hz, 2H), 10.4 (bs, 1H). MS (ESI): [M+1]
+
=213.19.  
5.1.2.9. 2-(3-Chlorobenzoyl)hydrazinecarboximidamide (7i). Synthesized according to 
method A, compound 7i was obtained as a yellow solid (yield 38%); mp 163-165 °C. 
1
H-NMR (d6-DMSO) : 6.77 (bs, 2H), 6.97 (bs, 2H), 7.29 (m, 2H), 7.86 (t, J=7.2 Hz, 
1H), 7.97 (s, 1H), 10.4 (s, 1H). MS (ESI): [M+1]
+
=213.31.  
5.1.2.10. 2-(4-Bromobenzoyl)hydrazinecarboximidamide (7j). Synthesized according to 
method A, compound 7j was obtained as a yellow solid (yield 41%); mp 199-201 °C. 
1
H-NMR (d6-DMSO) : 6.76 (bs, 2H), 6.91 (bs, 2H), 7.43 (d, J=7.8 Hz, 2H), 7.86 (d, 
J=7.8 Hz, 2H), 10.4 (bs, 1H). MS (ESI): [M]
+
=257.16 and 259.26.  
5.1.2.11. 2-(4-Methylbenzoyl)hydrazinecarboximidamide (7k). Synthesized according to 
method A, compound 7k was obtained as a white solid (yield 64%); mp 179-181 °C. 
1
H-
NMR (d6-DMSO) : 2.30 (s, 3H), 6.97 (bs, 4H), 7.10 (d, J=8.0 Hz, 2H), 7.79 (s, 2H), 
10,.3 (bs, 1H). MS (ESI): [M+1]
+
=193.25.  
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5.1.2.12. 2-(3-Methylbenzoyl)hydrazinecarboximidamide (7l). Synthesized according to 
method A, compound 7l was obtained as a pink solid (yield 67%); mp 161-162 °C. 
1
H-
NMR (d6-DMSO) : 2.31 (s, 3H), 7.08 (bs, 4H), 7.15 (m, 2H), 7.63 (t, J=7.6 Hz, 1H), 
7.77 (s, 1H), 10.1 (bs, 1H), 7.84 (bs, 2H). MS (ESI): [M+1]
+
=193.25. 
5.1.2.13. 2-(2-Methylbenzoyl)hydrazinecarboximidamide (7m). Synthesized according 
to method A, compound 7m was obtained as a white solid (yield 52%); mp 105-107 °C. 
1
H-NMR (d6-DMSO) : 6.57 (bs, 2H), 6.72 (bs, 2H), 7.11 (d, J=7.4 Hz, 1H), 7.26 (m, 
2H), 7.42 (d, J=7.4 Hz, 1H), 10.1 (bs, 1H). MS (ESI): [M+1]
+
=193.25.  
5.1.2.14. 2-(4-Ethylbenzoyl)hydrazinecarboximidamide (7n). Synthesized according to 
method A, compound 7n was obtained as a yellow solid (yield 43%); mp 170-171 °C. 
1
H-NMR (d6-DMSO) : 1.14 (t, J=7.4 Hz, 3H), 2.58 (q, J=7.4 Hz, 2H), 6.92 (bs, 4H), 
7.10 (d, J=8.0 Hz, 2H), 7.81 (d, J=8.0 Hz, 2H), 10.4 (bs, 1H). MS (ESI): 
[M+1]
+
=207.24.  
5.1.2.15. 2-(4-Methoxybenzoyl)hydrazinecarboximidamide (7o). Synthesized according 
to method A, compound 7o was obtained as a yellow solid (yield 45%); mp 183-185 °C. 
1
H-NMR (d6-DMSO) : 3.73 (s, 3H), 6.78 (bs, 4H), 6.84 (d, J=8.8 Hz, 2H), 7.81 (d, 
J=8.8 Hz, 2H), 10.3 (bs, 1H). MS (ESI): [M+1]
+
=209.22.  
5.1.2.16. 2-(3-Methoxybenzoyl)hydrazinecarboximidamide (7p). Synthesized according 
to method A, compound 7p was obtained as a white solid (yield 45%); mp 169-171 °C. 
1
H-NMR (d6-DMSO) : 3.76 (s, 3H), 6.80 (bs, 3H), 6.84 (bs, 2H), 7.17 (t, J=8.0 Hz, 
1H), 7.49 (s, 1H), 7.54 (d, J=8.0 Hz, 1H), 10.4 (bs, 1H). MS (ESI): [M+1]
+
=209.10. 
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5.1.2.17. 2-(4-Ethoxybenzoyl)hydrazinecarboximidamide (7q). Synthesized according to 
method A, compound 7q was obtained as a white solid (yield 48%); mp 150-152 °C. 
1
H-
NMR (d6-DMSO) : 1.29 (t, J=6.8 Hz, 3H), 4.01 (q, J=6.8 Hz, 2H), 6.79 (d, J=8.8 Hz, 
2H), 6.88 (bs 2H), 7.82 (bs, 2H), 7.82 (d, J=8.8 Hz, 2H), 10.4 (bs, 1H). MS (ESI): 
[M+1]
+
=223.09.  
5.1.2.18. 2-(4-Cyanobenzoyl)hydrazinecarboximidamide (7r). Synthesized according to 
method A, compound 7r was obtained as a yellow solid (yield 63%); mp 163-165 °C. 
1
H-NMR (d6-DMSO) : 6.87 (bs, 2H), 7.07 (bs, 2H), 7.73 (d, J=8.0 Hz, 2H), 8.14 (d, 
J=8.0 Hz, 2H), 10.2 (bs, 1H). 
13
C-NMR (d6-DMSO) : 110.34, 118.14*, 118.87, 125.75 
(2C), 126.09* (2C). 127.55*, 128.23*, 128.91* (2C), 132.51 (2C), 132.67*, 132.85*, 
133.36*, 136.50, 157.62. (*: signals of minor tautomer). MS (ESI): [M+1]
+
=204.27.  
5.1.2.19. 2-(3-Cyanobenzoyl)hydrazinecarboximidamide (7s). Synthesized according to 
method A, compound 7s was obtained as a yellow solid (yield 54%); mp 182-184 °C. 
1
H-NMR (d6-DMSO) : 6.66 (bs, 2H), 7.04 (bs, 2H), 7.49 (t, J=7.4 Hz, 1H), 7.68 (d, 
J=7.4 Hz, 1H), 8.02 (d, J=7.4 Hz, 1H), 8.39 (s, 1H), 10.1 (bs, 1H). 
13
C-NMR (d6-
DMSO) : 111.57, 118.61, 128.30, 129.66, 129.86, 131.64, 133.40, 156.60*, 157.53. 
(*: signals of minor tautomer). MS (ESI): [M+1]
+
=204.27.  
5.1.2.20. 2-(4-Nitrobenzoyl)hydrazinecarboximidamide (7t). Synthesized according to 
method A, compound 7t was obtained as a red solid (yield 56%); mp 163-165 °C. 
1
H-
NMR (d6-DMSO) : 6.62 (bs, 2H), 7.22 (bs, 2H), 8.14 (d, J=8.8 Hz, 2H), 8.23 (d, 
J=8.8 Hz, 2H), 10.2 (bs, 1H). MS (ESI): [M]
+
=224.21.  
5.1.3. General method B for the preparation of compounds 8a-t.  
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A stirred suspension of the appropriate aryl/heteroaryl aminoguanidine 7a-t (1 mmol) in 
water (5 mL) was placed in a 10 mL closed vial. The vessel was introduced into the 
microwave cavity (Pmax=250 psi) using a CEM Discover microwave apparatus. Starting 
microwave irradiation of 100 W was used, the temperature being ramped from 25 to 100 
°C in 2 min, with rapid stirring and venting. Once 100 °C was reached, the reaction 
mixture was held at this temperature for 10 min (Power: 100 W). After cooling, the 
precipitated product was filtered, washed with cold water and dried over P2O5, to furnish 
the appropriate 3-aryl-/heteroaryl-5-amino-1H-1,2,4-triazole derivatives 8a-t. For the 
characterization of compound 8a-h, 8k and 8o, see reference 41. In addition, 
compounds 8i [30] and 8j [42] have shown to possess spectroscopic and analytical data 
as previously reported. 
5.1.3.1. 3-(3-Tolyl)-1H-1,2,4-triazol-5-amine (8l). Synthesized according to method B, 
compound 8l was obtained as a white solid (yield 63%); mp 167-168 °C. 
1
H-NMR (d6-
DMSO) : 2.33 (s, 3H), 6.03 (bs, 2H), 7.12 (d, J=7.0 Hz, 1H), 7.23 (t, J=7.0 Hz, 1H), 
7.65 (m, 2H), 12.0 (bs, 1H). 
13
C-NMR (d6-DMSO) : 20.97, 122.39, 125.83, 128.14, 
128.63, 132.18, 137.22, 157.10, 158.33. MS (ESI): [M+1]
+
=175.29. 
5.1.3.2. 3-(2-Tolyl)-1H-1,2,4-triazol-5-amine (8m). Synthesized according to method B, 
compound 8m was obtained as a white solid (yield 75%); mp 194-195 °C. 
1
H-NMR (d6-
DMSO) : 2.48 (s, 3H), 6.01 (bs, 2H), 7.23 (m, 3H), 7.82 (d, 1H), 12.1 (bs, 1H). 13C-
NMR (d6-DMSO) : 21.85, 125.34, 127.56, 128.46, 130.79, 131.22, 135.68, 156.38, 
159.23. MS (ESI): [M+1]
+
=175.29. 
5.1.3.3. 3-(4-Ethyphenyl)-1H-1,2,4-triazol-5-amine (8n). Synthesized according to 
method B, compound 8n was obtained as a yellow solid (yield 54%); mp 213-215 °C. 
  
 32 
1
H-NMR (d6-DMSO) : 1.16 (t, J=7.6 Hz, 3H), 2.57 (q, J=7.6 Hz, 2H), 5.95 (bs, 2H), 
7.18 (d, J=7.8 Hz, 2H), 7.38 (d, J=7.8 Hz, 2H), 12.1 (bs, 1H). 
13
C-NMR (d6-DMSO) : 
15.37, 27.87, 125.26 (2C), 126.43, 127.17, 127.68 (2C), 143.71, 158.86. MS (ESI): 
[M+1]
+
=189.28. 
5.1.3.4. 3-(3-Methoxyphenyl)-1H-1,2,4-triazol-5-amine (8p). Synthesized according to 
method B, compound 8p was obtained as a white solid (yield 70%); mp 178-179 °C. 
1
H-
NMR (d6-DMSO) : 3.78 (s, 3H), 6.06 (bs, 2H), 6.92 (d, J=7.2 Hz, 1H), 7.31 (t, J=7.2 
Hz, 1H), 7.45 (m, 2H), 12.1 (bs, 1H). 
13
C-NMR (d6-DMSO) : 54.95, 110.41, 114.51, 
117.68, 126.54, 129.58, 131.40, 133.56, 159.22. MS (ESI): [M+1]
+
=191.02. 
5.1.3.5. 3-(4-Ethoxyphenyl)-1H-1,2,4-triazol-5-amine (8q). Synthesized according to 
method B, compound 8q was obtained as a white solid (yield 78%); mp 212-214 °C. 
1
H-
NMR (d6-DMSO) : 1.33 (t, J=6.8 Hz, 3H), 4.03 (q, J=6.8 Hz, 2H), 5.89 (bs, 2H), 6.92 
(d, J=8.0 Hz, 2H), 7.76 (d, J=8.0 Hz, 2H), 12.0 (bs, 1H). 
13
C-NMR (d6-DMSO) : 
14.55, 63.90, 114.15 (2C), 122.56, 126.63 (2C), 141.68, 158.60, 159.56. MS (ESI): 
[M+1]
+
=205.26.  
5.1.3.6. 4-(5-Amino-1H-1,2,4-triazol-3-yl)benzonitrile (8r). Synthesized according to 
method B, compound 8r was obtained as a yellow solid (yield 56%); mp 282-284 °C. 
1
H-NMR (d6-DMSO) : 6.20 (bs, 2H), 7.83 (d, J=8.6 Hz, 2H), 8.01 (d, J=8.6 Hz, 2H), 
12.3 (s, 1H). 
13
C-NMR (d6-DMSO) : 110.34, 118.87, 125.75 (2C), 128.91, 132.51 
(2C), 136.50, 157.62. MS (ESI): [M+1]
+
=186.19.  
5.1.3.7. 3-(5-Amino-1H-1,2,4-triazol-3-yl)benzonitrile (8s). Synthesized according to 
method B, compound 8s was obtained as a white solid (yield 58%); mp 227-229 °C. 
1
H-
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NMR (d6-DMSO) : 6.19 (bs, 2H), 7.62 (t, J=7.8 Hz, 1H), 7.79 (d, J=7.8 Hz, 1H), 8.15 
(s, 1H), 8.19 (d, J=7.8 Hz, 1H), 12.3 (s, 1H). 
13
C-NMR (d6-DMSO) : 111.57, 118.61, 
128.30, 129.66, 129.86, 131.64, 133.40, 156.60, 157.53. MS (ESI): [M+1]
+
=186.31.  
5.1.3.8. 3-(4-Nitrophenyl)-1H-1,2,4-triazol-5-amine (8t). Synthesized according to 
method B, compound 8t was obtained as an orange solid (yield 45%); mp 274-276 °C. 
1
H-NMR (d6-DMSO) : 6.24 (bs, 2H), 8.08 (d, J=8.8 Hz, 2H), 8.25 (d, J=8.8 Hz, 2H), 
12.4 (bs, 1H). 
13
C-NMR (d6-DMSO) : 123.90 (2C). 126.06 (2C), 128.26, 138.36, 
146.89, 157.73. MS (ESI): [M+1]
+
=206.13. 
5.1.4. General method C for the synthesis of compounds 5a-v.  
To a stirred solution of the appropriate 1,2,4-triazole 8a-t (1 mmol) in dry pyridine (5 
mL) cooled at -5 °C was added 3’,4’,5’-trimethoxybenzoyl chloride (252 mg, 1.1 mol, 
1.1 equiv.) in small portions. For the preparation of compounds 5u and 5v, 3’,4’-
dimethoxybenzoyl chloride (221 mg, 1.1 mmol, 1.1 equiv.) or 4’-methoxybenzoyl 
chloride (188 mg, 1.1 mmol, 1.1 equiv.), respectively, were added to derivative 5k. The 
reaction mixture was kept for 30 min at -5 °C and then overnight at room temperature. 
Pyridine was removed by evaporation under reduced pressure. To the residue was added 
CH2Cl2, and the organic phase was washed with saturated aq. NaHCO3, water and brine 
and dried. The reaction mixture was filtered, and the solvent was removed in vacuo. The 
crude residue was suspended in ethyl ether (15 mL), the resulting suspension stirred for 
30 min, filtered and the residue filtered under reduced pressure to furnish the 1-aroyl-3-
aryl-5-amino-1H-1,2,4-triazole derivatives 5a-v. Compounds 5a, 5e, 5f and 5h were 
characterized by spectroscopic and analytical data, and our data were in agreement with 
those previously reported [30]. 
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5.1.4.1. (5-Amino-3-phenyl-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) methanone 
(5a). Synthesized according to method C, derivative 5a was obtained as a white solid 
(yield 66%); mp 225-227 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.87 (s, 6H), 7.47 
(m, 3H), 7.68 (s, 2H), 7.86 (bs, 2H), 8.03 (m, 2H). 
13
C-NMR (d6-DMSO) : 55.96 (2C), 
60.13, 108.92 (2C), 126.22 (2C), 126.42, 128.70 (2C), 130.02, 130.64, 141.60, 152.00 
(2C), 159.05, 159.40, 166.39. MS (ESI): [M+1]
+
=355.37. Anal. calcd for C18H18N4O4. 
C, 61.01; H, 5.12; N, 15.81; found: C, 60.78; H, 5.01; N, 15.67. 
5.1.4.2. (5-Amino-3-(thiophen-2-yl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5b). Synthesized according to method C, derivative 5b was obtained as a 
white solid (yield 42%); mp 190-192 °C. 
1
H-NMR (d6-DMSO) : 3.78 (s, 3H), 3.88 (s, 
6H), 7.18 (dd, J=5.0 and 3.8 Hz, 1H), 7.63 (m, 3H), 7.64 (d, J=3.8 Hz, 1H), 7.88 (bs, 
2H). 
13
C-NMR (d6-DMSO) : 55.99 (2C), 60.22, 109.05 (2C), 126.30, 127.56, 128.14, 
128.60, 133.04, 141.69, 152.05 (2C), 155.89, 158.98, 166.12. MS (ESI): 
[M+1]
+
=361.19. Anal. calcd for C16H16N4O4S. C, 53.32; H, 4,47; N, 15.55; found: C, 
53.14; H, 4.29; N, 15.40. 
5.1.4.3. (5-Amino-3-(furan-2-yl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5c). Synthesized according to method C, derivative 5c was obtained as a 
white solid (yield 54%); mp 212-214 °C. 
1
H-NMR (d6-DMSO) : 3.79 (s, 3H), 3.84 (s, 
6H), 6.64 (dd, J=3.2 and 1.6 Hz, 1H), 6.98 (d, J=3.2 Hz, 1H), 7.53 (m, 3H), 7.85 (bs, 
2H). 
13
C-NMR (d6-DMSO) : 56.00 (2C), 60.14, 108.78 (2C), 111.53, 111.76, 126.51, 
141.54, 144.74, 145.43, 152.01 (2C), 152.75, 158.71, 166.53. MS (ESI): 
[M+1]
+
=345.12. Anal. calcd for C16H16N4O5. C, 58.81; H, 4.68; N, 16.27; found: C, 
58.69; H, 4.49; N, 16.19. 
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5.1.4.4. (5-Amino-3-(pyridin-2-yl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5d). Synthesized according to method C, derivative 5d was obtained as a 
white solid (yield 62%); mp 227-229 °C. 
1
H-NMR (d6-DMSO) : 3.82 (s, 3H), 3.88 (s, 
6H), 7.42 (dd, J=5.2 and 1.6 H Hz, 1H), 7.58 (s, 2H), 7.82 (bs, 2H), 7.88 (t, J=5.2 Hz, 
1H), 8.02 (d, J=5.2 Hz, 1H), 8.63 (d, J=1.6 Hz, 1H). 
13
C-NMR (d6-DMSO) : 56.12 
(2C), 60.23, 108.99 (2C), 122.32, 124.72, 126.61, 137.06, 141.71, 148.96, 149.80, 
152.13 (2C), 159.08, 159.50, 166.94. MS (ESI): [M+1]
+
=356.48. Anal. calcd for 
C17H17N5O4. C, 57.46; H, 4.82; N, 19.71; found: C, 57.31; H, 4.67; N, 19.58. 
5.1.4.5. (5-Amino-3-(pyridin-3-yl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5e). Synthesized according to method C, derivative 5e was obtained as a 
white solid (yield 46%); mp 221-222 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.87 (s, 
6H), 7.51 (t, J=5.2 Hz, 1H), 7.61 (s, 2H), 7.94 (bs, 2H), 8.27 (d, J=5.2 Hz, 1H), 8.66 
(d, J=5.2 Hz, 1H), 9.13 (s, 1H). 
13
C-NMR (d6-DMSO) : 56.05 (2C), 60.20, 105.66, 
108.97 (2C), 123.99, 126.02, 126.32, 133.67, 147.31, 150.88, 152.09 (2C), 157.52, 
159.20, 166.46. MS (ESI): [M+1]
+
=356.36. Anal. calcd for C17H17N5O4. C, 57.46; H, 
4.82; N, 19.71; found: C, 57.21; H, 4.58; N, 19.39. 
5.1.4.6. (5-Amino-3-(pyridin-4-yl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5f). Synthesized according to method C, derivative 5f was obtained as a 
white solid (yield 51%); mp 227-229 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.87 (s, 
6H), 7.58 (s, 2H), 7.85 (dd, J=4.4 and 1.6 Hz, 2H), 7.96 (bs, 2H), 8.68 (m, 2H). 
13
C-
NMR (d6-DMSO) : 56.11 (2C), 60.25, 105.71, 109.01 (2C), 119.75, 120.39, 126.28, 
137.38, 150.37, 150.47, 152.13, 152.72, 157.71, 159.34, 166.61. MS (ESI): 
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[M+1]
+
=356.36. Anal. calcd for C17H17N5O4. C, 57.46; H, 4.82; N, 19.71; found: C, 
57.32; H, 4.70; N, 19.63. 
5.1.4.7. (5-Amino-3-(4-fluorophenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl 
)methanone (5g). Synthesized according to method C, compound 5g was obtained as a 
white solid (yield 64%); mp 248-250 °C. 
1
H-NMR (d6-DMSO) : 3.79 (s, 3H), 3.86 (s, 
6H), 7.32 (t, J=6.8 Hz, 2H), 7.60 (s, 2H), 7.88 (bs, 2H), 8.01 (t, J=6.8 Hz, 2H). 
13
C-
NMR (d6-DMSO) : 55.98 (2C), 60.14, 108.87 (2C), 115.66 (J=85.2 Hz), 126.42, 
126,60, 128.48, 128.57, 141.59, 152.01 (2C), 158.61, 159.09, 161.91, 164.36, 166.43. 
MS (ESI): [M+1]
+
=373.2. Anal. calcd for C18H17FN4O4. C, 58.06; H, 4.60; N, 15.05; 
found: C, 57.93; H, 4.46; N, 14.89. 
5.1.4.8. (5-Amino-3-(4-chlorophenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5h). Synthesized according to method C, compound 5h was obtained as a 
white solid (yield 51%); mp 217-219 °C. 
1
H-NMR (d6-DMSO) : 3.78 (s, 3H), 3.86 (s, 
6H), 7.52 (d, J=8.8 Hz, 2H), 7.56 (s, 2H), 7.86 (bs, 2H), 7.94 (d, J=8.8 Hz, 2H). 
13
C-
NMR (d6-DMSO) : 55.97 (2C), 60.15, 108.86 (2C), 126.39, 127.97 (2C), 128.88 (2C), 
134.64 (2C), 141.60, 152.01 (2C), 158.49, 159.09, 166.45. MS (ESI): [M+1]
+
=389.3. 
Anal. calcd for C18H17ClN4O4. C, 55.60; H, 4.41; N, 14.41; found: C, 55.38; H, 4.29; N, 
14.30. 
5.1.4.9. (5-Amino-3-(3-chlorophenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5i). Synthesized according to method C, compound 5i was obtained as a 
white solid (yield 59%); mp 239-241 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.87 (s, 
6H), 7.54 (m, 2H), 7.60 (s, 2H), 7.91 (m, 4H). 
13
C-NMR (d6-DMSO) : 55.95 (2C), 
60.15, 108.92 (2C), 124.73, 125.80, 126.28, 129.81, 130.84, 132.14, 133.36, 141.66, 
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152.00 (2C), 158.13, 159.10, 166.40. MS (ESI): [M+1]
+
=389.43. Anal. calcd for 
C18H17ClN4O4. C, 55.60; H, 4.41; N, 14.41; found: C, 55.42; H, 4.30; N, 14.28.  
5.1.4.10. (5-Amino-3-(4-bromophenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5j). Synthesized according to method C, compound 5j was obtained as a 
white solid (yield 59%); mp 219-220 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.86 (s, 
6H), 7.58 (s, 2H), 7.70 (d, J=8.4 Hz, 2H), 7.86 (bs, 2H), 7.88 (d, J=8.4 Hz, 2H). 
13
C-
NMR (d6-DMSO) : 56.08 (2C), 60.23, 108.96 (2C), 123.51, 126.47, 128.30 (2C), 
129.38, 131.88 (2C), 141.70, 152.10 (2C), 158.66, 159.17, 166.53. MS (ESI): 
[M]
+
=433.27 and 435.38. Anal. calcd for C18H17BrN4O4. C, 49.90; H, 3.95; N, 12.93; 
found: C, 49.77; H, 3.78; N, 12.81. 
5.1.4.11. (5-Amino-3-(p-tolyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5k). Synthesized according to method C, compound 5k was obtained as a 
white solid (yield 42%); mp 208-209 °C. 
1
H-NMR (d6-DMSO) : 2.33 (s, 3H), 3.78 (s, 
3H), 3.84 (s, 6H), 7.26 (d, J=8.0 Hz, 2H), 7.60 (s, 2H), 7.81 (bs, 2H), 7.83 (d, J=8.0 
Hz, 2H). 
13
C-NMR (d6-DMSO) : 21.02, 56.04 (2C), 60.23, 108.99 (2C), 126.28 (2C), 
126.57, 127.40, 129.37 (2C), 139.79, 141.65, 152.08 (2C), 159.08, 159.56, 166.45. MS 
(ESI): [M+1]
+
=369.49. Anal. calcd for C19H20N4O4. C, 61.95; H, 5.47; N, 15.21; found: 
C, 61.81; H, 5.35; N, 15.01. 
5.1.4.12. (5-Amino-3-(m-tolyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5l). Synthesized according to method C, compound 5l was obtained as a 
white solid (yield 54%); mp 216-218 °C. 
1
H-NMR (d6-DMSO) : 2.36 (s, 3H), 3.80 (s, 
3H), 3.87 (s, 6H), 7.29 (d, J=7.6 Hz, 1H), 7.35 (t, J=7.6 Hz, 1H), 7.64 (s, 2H), 7.71 (d, 
J=7.6 Hz, 1H), 7.80 (s, 1H), 7.84 (bs, 2H). 
13
C-NMR (d6-DMSO) : 20.92, 55.93 (2C), 
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60.14, 108.95 (2C), 123.40, 126.41, 126.78, 128.61, 129.99, 130.66, 137.81, 141.61, 
151.99 (2C), 159.00, 159.48, 166.33. MS (ESI): [M+1]
+
=369.36. Anal. calcd for 
C19H20N4O4. C, 61.95; H, 5.47; N, 15.21; found: C, 61.79; H, 5.38; N, 15.05. 
5.1.4.13. (5-Amino-3-(o-tolyl)-1H-1,2,4-triazol-1-yl)(3,4,5-
trimethoxyphenyl)methanone (5m). Synthesized according to method C, compound 5m 
was obtained as a white solid (yield 75%); mp 193-195 °C. 
1
H-NMR (d6-DMSO) : 2.62 
(s, 3H), 3.78 (s, 3H), 3.86 (s, 6H), 7.25 (m, 3H), 7.58 (s, 2H), 7.82 (bs, 2H), 8.00 (d, 
J=7.6 Hz, 1H). 
13
C-NMR (d6-DMSO) : 22.23, 56.07 (2C), 60.23, 108.85 (2C), 125.85, 
126.79, 128.98, 129.44 (2C), 131.23, 136.82, 141.71, 152.10 (2C), 158.23, 160.41, 
166.70. MS (ESI): [M+1]
+
=369.24. Anal. (C19H20N4O4) C, H, N. Anal. calcd for 
C19H20N4O4. C, 61.95; H, 5.47; N, 15.21; found: C, 61.77; H, 5.29; N, 15.05. 
5.1.4.14. (5-Amino-3-(4-ethylphenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5n). Synthesized according to method C, compound 5n was obtained as a 
white solid (yield 52%); mp 171-173 °C. 
1
H-NMR (d6-DMSO) : 1.20 (t, J=7.6 Hz, 
3H), 2.64 (q, J=7.6 Hz, 2H), 3.80 (s, 3H), 3.86 (s, 6H), 7.31 (d, J=8.0 Hz, 2H), 7.63 (s, 
2H), 7.82 (bs, 2H), 7.88 (d, J=8.0 Hz, 2H). 
13
C-NMR (d6-DMSO) : 15.25, 27.98, 
55.96 (2C), 60.15, 108.92 (2C), 126.29 (2C), 126.46, 127.56, 128.10 (2C), 141.56, 
145.92, 151.99 (2C), 159.00, 159.48, 166.33. MS (ESI): [M+1]
+
=383.48. Anal. calcd 
for C20H22N4O4. C, 62.82; H, 5.80; N, 14.65; found: C, 62.71; H, 5.69; N, 14.52. 
5.1.4.15. (5-Amino-3-(4-methoxyphenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-
trimethoxyphenyl) methanone (5o). Synthesized according to method C, compound 5o 
was obtained as a white solid (yield 66%); mp 206-208 °C. 
1
H-NMR (d6-DMSO) : 3.79 
(s, 3H), 3.80 (s, 3H), 3.87 (s, 6H), 7.03 (d, J=9.2 Hz, 2H), 7.63 (s, 2H), 7.83 (bs, 2H), 
  
 39 
7.90 (d, J=9.2 Hz, 2H). 
13
C-NMR (d6-DMSO) : 55.14, 55.95 (2C), 60.12, 108.91 (2C), 
114.10 (2C), 122.47, 126.51, 127.81 (2C), 141.53, 151.98 (2C), 158.98, 159.12, 
160.68, 166.27. MS (ESI): [M+1]
+
=385.22. Anal. calcd for C19H20N4O5. C, 59.37; H, 
5.24; N, 14.58; found: C, 59.25; H, 5.11; N, 14.47. 
5.1.4.16. (5-Amino-3-(3-methoxyphenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-
trimethoxyphenyl) methanone (5p). Synthesized according to method C, compound 5p 
was obtained as a white solid (yield 69%); mp 199-200 °C. 
1
H-NMR (d6-DMSO) : 3.80 
(s, 3H), 3.81 (s, 3H), 3.87 (s, 6H), 7.03 (m, 1H), 7.40 (t, J=8.0 Hz, 1H), 7.49 (d, J=1.6 
Hz, 1H), 7.56 (m, 1H), 7.66 (s, 2H), 7.87 (bs, 2H). 
13
C-NMR (d6-DMSO) : 54.95, 
55.93 (2C), 60.16, 109.01 (2C), 110.92, 116.10, 118.58, 126.32, 129.92 (2C), 131.40, 
141.66, 152.01 (2C), 159.06, 159.28, 166.26. MS (ESI): [M+1]
+
=385.34. Anal. calcd 
for C19H20N4O5. C, 59.37; H, 5.24; N, 14.58; found: C, 59.28; H, 5.09; N, 14.40. 
5.1.4.17. (5-Amino-3-(4-ethoxyphenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5q). Synthesized according to method C, compound 5q was obtained as a 
white solid (yield 69%); mp 196-198 °C. 
1
H-NMR (d6-DMSO) : 1.34 (t, J=7.2 Hz, 
3H), 3.79 (s, 3H), 3.86 (s, 6H), 4.06 (q, J=7.2 Hz, 2H), 7.00 (d, J=8.8 Hz, 2H), 7.62 (s, 
2H), 7.82 (bs, 2H), 7.88 (d, J=8.8 Hz, 2H). 
13
C-NMR (d6-DMSO) : 14.50, 55.95 (2C), 
60.12, 63.08, 108.89 (2C), 114.50 (2C), 122.31, 126.53, 127.81 (2C), 141.52, 151.98 
(2C), 158.97, 159.35, 159.97, 166.29. MS (ESI): [M+1]
+
=399.46. Anal. calcd for 
C20H22N4O5. C, 60.29; H, 5.57; N, 14.06; found: C, 60.12; H, 5.39; N, 13.89. 
5.1.4.18. 4-(5-Amino-1-(3,4,5-trimethoxybenzoyl)-1H-1,2,4-triazol-3-yl)benzonitrile 
(5r). Synthesized according to method C, compound 5r was obtained as a yellow solid 
(yield 63%); mp 248-250 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.86 (s, 6H), 7.57 
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(s, 2H), 7.94 (bs, 2H), 7.96 (d, J=8.0 Hz, 2H), 8.10 (d, J=8.0 Hz, 2H). 
13
C-NMR (d6-
DMSO) : 55.99 (2C), 60.14, 108.86 (2C), 112.21, 118.48, 126.25, 126.86 (2C), 
132.80 (2C), 134.35, 141.68, 152.01 (2C), 157.96, 159.17, 166.52. MS (ESI): 
[M]
+
=380.28. Anal. calcd for C19H17N5O4. C, 60.14; H, 4.52; N, 18.46; found: C, 60.01; 
H, 4.37; N, 18.29. 
5.1.4.19. 3-(5-amino-1-(3,4,5-trimethoxybenzoyl)-1H-1,2,4-triazol-3-yl)benzonitrile 
(5s). Synthesized according to method C, compound 5s was obtained as a white solid 
(yield 92%); mp 185-187 °C. 
1
H-NMR (d6-DMSO) : 3.80 (s, 3H), 3.87 (s, 6H), 7.58 
(s, 2H), 7.72 (t, J=7.8 Hz, 1H), 7.94 (m, 3H), 8.24 (m, 2H). 
13
C-NMR (d6-DMSO) : 
56.52 (2C), 60.69, 109.42 (2C), 112.46, 118.81, 126.80, 129.62, 130.03, 130.72, 
131.19, 131.84, 134.06, 142.23, 152.58, 158.26, 159.72, 167.04. MS (ESI): 
[M+1]
+
=380.26. Anal. calcd for C19H17N5O4. C, 60.14; H, 4.52; N, 18.46; found: C, 
60.00; H, 4.40; N, 18.31. 
5.1.4.20. (5-Amino-3-(4-nitrophenyl)-1H-1,2,4-triazol-1-yl) (3,4,5-trimethoxyphenyl) 
methanone (5t). Synthesized according to method C, compound 5t was obtained as a 
yellow solid (yield 40%); mp 218-220 °C. 
1
H-NMR (d6-DMSO) : 3.82 (s, 3H), 3.87 (s, 
6H), 7.58 (s, 2H), 7.95 (bs, 2H), 8.18 (d, J=8.8 Hz, 2H), 8.33 (d, J=8.8 Hz, 2H). 
13
C-
NMR (d6-DMSO) : 56.57 (2C), 60.70, 109.40 (2C), 124.68 (2C), 126.80, 127.92 (2C), 
136.65, 142.22, 148.66, 152.58 (2C), 158.26, 159.78, 167.11. MS (ESI): [M]
+
=400.33. 
Anal. calcd for C18H17N5O6. C, 54.14; H, 4.29; N, 17.54; found: C, 54.01; H, 4.12; N, 
17.38. 
5.1.4.21. (5-Amino-3-(p-tolyl)-1H-1,2,4-triazol-1-yl)(3,4-dimethoxyphenyl)methanone 
(5u). Synthesized according to method C, compound 5u was obtained as a white solid 
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(yield 55%); mp 201-203 °C. 
1
H-NMR (d6-DMSO) : 2.32 (s, 3H), 3.80 (s, 3H), 3.84 
(s, 3H), 7.14 (d, J=8.0 Hz, 1H), 7.30 (d, J=8.0 Hz, 2H), 7.78 (bs, 2H), 7.92 (m, 3H), 
8.05 (d, J=8.0 Hz, 1H). 
13
C-NMR (d6-DMSO) : 21.02, 55.51, 55.79, 110.75 (2C), 
114.17, 123.57, 125.99, 126.31, 127.48, 129.31 (2C), 139.72, 147.77, 153.05, 159.11, 
159.43, 166.36. MS (ESI): [M+1]
+
=339.52. Anal. calcd for C18H18N4O3. C, 63.89; H, 
5.36; N, 16.56; found: C, 63.78; H, 5.22; N, 16.45. 
5.1.4.22. (5-Amino-3-(p-tolyl)-1H-1,2,4-triazol-1-yl)(4-methoxyphenyl)methanone (5v). 
Synthesized according to method C, compound 5v was obtained as a white solid (yield 
50%); mp 180-182 °C. 
1
H-NMR (d6-DMSO) : 2.33 (s, 3H), 3.86 (s, 3H), 7.09 (dd, 
J=8.8 and 2.4 Hz, 2H), 7.28 (d, J=8.4 Hz, 2H), 7.76 (bs, 2H), 7.84 (d, J=8.4 Hz, 2H), 
8.24 (dd, J=8.8 and 2.4 Hz, 2H). 
13
C-NMR (d6-DMSO) : 21.03, 55.60, 113.56 (2C), 
123.83, 126.37 (2C), 127.46, 129.25 (2C), 133.63 (2C), 139.71, 159.04, 159.46, 
163.14, 166.49. MS (ESI): [M+1]
+
=309.54. Anal. calcd for C17H16N4O2. C, 66.22; H, 
5.23; N, 18.17; found: C, 66.12; H, 5.08; N, 18.02. 
5.2. Biological assays and computational studies 
5.2.1. Cell growth conditions and antiproliferative assay. 
Human T-leukemia (Jurkat) and human B-leukemia (RS4;11) cells were grown in 
RPMI-1640 medium (Gibco, Milano, Italy). Breast adenocarcinoma (MCF-7), human 
cervix carcinoma (HeLa), and human colon adenocarcinoma (HT-29) cells were grown 
in DMEM medium (Gibco, Milano, Italy), all supplemented with 115 units/mL 
penicillin G (Gibco, Milano, Italy), 115 μg/mL streptomycin (Invitrogen, Milano, 
Italy), and 10% fetal bovine serum (Invitrogen, Milano, Italy). Stock solutions (10 mM) 
of the different compounds were obtained by dissolving them in DMSO. Individual 
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wells of a 96-well tissue culture microtiter plate were inoculated with 100 μL of 
complete medium containing 8 × 10
3
 cells. The plates were incubated at 37 °C in a 
humidified 5% CO
2
 incubator overnight prior to the experiments. After medium 
removal, 100 μL of fresh medium containing the test compound at different 
concentrations was added to each well in triplicate and incubated at 37 °C for 72 h. Cell 
viability was assayed by the (3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide test as previously described [43].  
5.2.2. Effects on tubulin polymerization and on colchicine binding to tubulin.  
Bovine brain tubulin was purified as described previously [44].
 
To evaluate the effect of 
the compounds on tubulin assembly in vitro [45], varying concentrations were 
preincubated with 10 M tubulin in glutamate buffer at 30 ˚C and then cooled to 0 ˚C. 
After addition of GTP, the mixtures were transferred to 0 C cuvettes in a recording 
spectrophotometer and warmed to 30 °C, and the assembly of tubulin was observed 
turbidimetrically. The IC
50
 was defined as the compound concentration that inhibited 
the extent of assembly by 50% after a 20 min incubation. The capacity of the test 
compounds to inhibit colchicine binding to tubulin was measured as described [46], 
except that the reaction mixtures contained 1 M tubulin, 5 M [
3
H]colchicine and 5 
M test compound. 
5.2.3. Molecular modeling.  
All molecular docking studies were performed on a Viglen Genie Intel®Core
TM
 i7-3770 
vPro CPU@ 3.40 GHz x 8 running Ubuntu 14.04. Molecular Operating Environment 
(MOE) 2015.10 and Maestro (Schrödinger Release 2017-1) were used as molecular 
modeling software. The tubulin structures were downloaded from the PDB data bank 
(http://www.rcsb.org/; PDB code 4O2B, 3N2G). The proteins were preprocessed using 
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the Schrödinger Protein Preparation Wizard by assigning bond orders, adding 
hydrogens and performing a restrained energy minimization of the added hydrogens 
using the OPLS_2005 force field. Ligand structures were built with MOE and then 
prepared using the Maestro LigPrep tool by energy minimizing the structures 
(OPLS_2005 force filed), generating possible ionization states at pH 7±2, generating 
tautomers and low-energy ring conformers. After isolating a tubulin dimer structure, 
two 12 Å docking grids (inner-box 10 Å and outer-box 22 Å) were prepared using as 
centroid the co-crystallized colchicine in the 4O2B structure and the co-crystallized 
G2N in the 3N2G protein. Molecular docking studies were performed using Glide SP 
precision keeping the default parameters and setting 6 as number of output poses per 
input ligand to include in the solution. The output poses were then refined with Glide 
XP scoring and the output database saved as a mol2 file. The docking results were 
visually inspected for their ability to bind the active site. MD simulations were 
performed on Supermicro Intel®Xeon® CPU ES-46200 @ 2.20 GHz x 12 running 
Ubuntu 14.04 using the Desmond package for MD simulation: OPLS-AA force field in 
explicit solvent, employing the TIP3 water model was used. The initial coordinates for 
the MD simulation were taken from the best docking experiment result for each single 
compound. A cubic water box was used for the solvation of the system, ensuring a 
buffer distance of approximately 10 Å between each box side and the complex atoms. 
The system was neutralized adding either 21 (4O2B) or 24 (3N2G) sodium counter 
ions. The system was minimized and pre-equilibrated using the default relaxation 
routine implemented in Desmond. A 20 ns MD simulation was performed, during 
which the equations of motion were integrated using a 2 fs time step in the NPT 
ensemble, with temperature (300 K) and pressure (1 atm) constant. All other parameters 
were set using the Desmond default values. Data were collected every 8 ps (energy) and 
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every 32 ps (trajectory). Each protein-ligand complex simulation was performed in 
triplicate, using each time a random seed as starting point. Visualization of protein-
ligand complex and MD trajectory analysis was carried out using Maestro, and the 
RMSD analyses were performed using the Simulation Event Analysis tool and the 
Simulation Interaction Diagram of Desmond. The ∆G
binding
 values of the protein-ligand 
complex were calculated using the MM/GBSA method as implemented in the Prime 
module from Maestro using the default settings and the Maestro script 
termal_mmgbsa.py. Briefly, the script takes in the MD trajectory from the last 14 ns of 
simulation, splits it into individual frame snapshots (extracted every 0.064 ns, for a total 
of 220 frames), and runs each one through MMGBSA (after deleting waters and 
separating the ligand from the receptor). For each single simulation, an average ∆G
binding
 
value for the 14 ns is calculated.  
5.2.4 Flow cytometric analysis of cell cycle distribution.  
5 × 10
5
 HeLa cells were treated with different concentrations of the test compounds for 
24 h. After the incubation period, the cells were collected, centrifuged, and fixed with 
ice-cold ethanol (70%). The cells were then treated with lysis buffer containing RNase A 
and 0.1% Triton X-100 and then stained with PI. Samples were analyzed on a Cytomic 
FC500 flow cytometer (Beckman Coulter). DNA histograms were analyzed using 
MultiCycle for Windows (Phoenix Flow Systems). 
5.2.5 Apoptosis assay. 
Cell death was determined by flow cytometry of cells double stained with annexin 
V/FITC and PI. The Coulter Cytomics FC500 (Beckman Coulter) was used to measure 
the surface exposure of phosphatidyl serine on apoptotic cells according to the 
manufacturer’s instructions (Annexin-V Fluos, Roche Diagnostics). 
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5.2.6. Statistical analysis.  
Unless indicated differently, the results are presented as mean ± S.E.M. The differences 
between different treatments were analyzed using the two-sided Student’s t test. P 
values lower than 0.05 were considered significant. 
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Highlights 
Chemical modification of different substituted aryl groups at the 3-
position of 1,2,4-triazole ring was investigated.  
Compounds 5k and 5o bind to the colchicine binding site and inhibit the 
polymerization of tubulin. 
Compound 5k was 2-fold more potent than CA-4 as inhibitor of tubulin 
assembly. 
For the most active compounds 5k and 5o, a good correlation was 
observed between antiproliferative activities, inhibition tubulin 
polymerization and colchicine binding. 
Derivatives 5p and 5j may exert their potent antiproliferative effect by a 
mechanism other than inhibition of tubulin polymerization.
 
 
